Study of new drug for advanced solid tumors with certain genetic markers
Treatments studied
Part of Cancer, Digestive system clinical trials.
This trial is testing a new oral medication, VVD-133214, for people with advanced solid tumors that have a specific genetic feature called MSI-high or dMMR. The study will see if the drug is safe and effective when given alone or with other drugs like bevacizumab or pembrolizumab.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have a type of cancer that is advanced (has spread or cannot be removed with surgery) and has a specific marker called MSI-high or dMMR.
- You need to be able to take care of yourself (able to do most daily activities) — this is called 'performance status 0 or 1'.
- If taking the study drug alone: you must have tried at least 2 standard cancer treatments that no longer worked or caused too many side effects.
- For the combination with bevacizumab: you must have colorectal cancer that has not responded to 2–3 previous treatments (including chemo and possibly immunotherapy).
- For the combination with pembrolizumab: you must have colorectal cancer that is locally advanced or has spread, and you haven't had any treatment for the metastatic disease yet.
- You need to have at least one tumor that can be measured on a scan, and be expected to live at least 3 months.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This Phase 1 trial tests VVD-130037, a new experimental medicine, to see if it is safe and tolerable in people with advanced (metastatic or unresectable) solid cancers. If you have already tried standard treatments and your body can handle study medication, you may be eligible—especially for certain lung, head and neck, or esophageal cancer types with specific genetic changes.
This study tests an experimental drug called VVD-159642 in people with advanced solid tumors that have specific genetic changes (RAS or EGFR alterations, or HER2 overexpression). The goal is to see if the drug is safe and tolerable.
This study tests a new drug combination for people with advanced solid tumors that have not responded to other treatments. It aims to see if the combination is safe and effective.
This trial tests a new combination of drugs (liposomal irinotecan, 5-FU/LV, and bevacizumab) for people with advanced colorectal cancer that cannot be removed by surgery. The goal is to see if this treatment is safe and effective in shrinking tumors and improving outcomes.
This trial tests a new drug combined with a standard treatment for advanced colorectal cancer that has not responded to earlier therapies. It aims to see if the combination can help slow the cancer's growth.
This trial tests a new drug called MRG007 for people with advanced solid tumors that haven't responded to other treatments. The drug targets a protein called CDH17 on cancer cells; you need a tumor sample to check for it.
Hear when a new Colorectal cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.